AI-Based Remote Test for Parkinson’s Disease Severity Shows Promise

By Michael Awood

September 17, 2023

People with Parkinson’s disease rarely receive proper care because of a lack of access to neurological care. In the US, about 40% of those aged 65 or older with PD do not receive care from a neurologist. Access is even more limited in developing regions. Experts suggest an AI-based method to measure Parkinson’s disease severity using a remote finger-tapping test.

Researchers developed a model that uses AI techniques to evaluate motor performance severity of patients. Through performing finger-tapping tasks at home, they analysed the patients with a webcam. A panel of experts and non-experts validated its features, which correlated strongly with the experts’ ratings.

This research shows that remote assessment of the finger-tapping task can be done with reliability. AI models have the potential to perform as well as clinicians and outperform non-specialists in assessing the task, according to the study. The model had an equal performance for all subgroups, suggesting its potential wide adoption in movement disorders.

The tool could enable longitudinal tracking of symptom progression, helping to fine-tune PD treatment. Clinical visits can use it to track PD progression and augment neurologists’ ability to analyze videos with digital biomarkers. In areas with a scarcity of neurologists, the tool could assess symptoms frequently and refer the patient to a neurologist if necessary.

However, the model was not without its limitations. Sometimes, it misclassified severity scores and showed poor accuracy. The model worked well in both high and low-quality videos, making it difficult to evaluate videos taken outside clinical settings. Researchers emphasised ethical considerations as data security, user privacy, and algorithmic bias. When introducing the tool in healthcare settings, these need reviewing.

The researchers also suggest future improvements. These included addressing the impact of tremors on finger-tapping, increasing the sample size, and balancing severity scores as a few improvements to the study.

 

Cover image taken from the research article

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.